A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients
Status:
Recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
Breast cancer is the most common malignant tumor in women. Recurrent or metastatic breast
cancer is incurable. High risk patients usually have the following characteristics, such as,
non-pCR after neoadjuvant therapy, lymph nodes positive, >2cm tumor size, HER2
overexpression, etc. Intensive targeted or chemo therapy could improve prognosis. Previous
studies have shown the efficacy and feasibility of intensive treatment of capecitabine in
non-pCR breast cancer patients. Given the metronomic capecitabine therapy is well tolerated,
we designed this study to compare the efficacy and safety of adding metronomic capecitabine
to standard adjuvant therapy for high risk HER2+ breast cancer patients.